SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune
responses from destroying the cancer. This study will be the first study to begin to
determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This
first study will enroll participants with melanoma, as melanoma cancer has been shown to be
able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective
treatment of melanoma. It is thought that SX-682 will block MDSCs from going to the cancer,
and thus will allow a patient's own immune system to attack the cancer.
The first participants enrolled in the study will receive for 21 days SX-682 as monotherapy.
After 21 days participants will receive pembrolizumab therapy (an approved immunotherapy for
melanoma) and will remain in the study for evaluations for 3 months.
After these participants complete the monotherapy stage, the next participants will receive
SX-682 and pembrolizumab together as combination therapy. These participants will receive the
combination therapy and be evaluated in the study for approximately 2 years.
Phase:
Phase 1
Details
Lead Sponsor:
Syntrix Biosystems, Inc.
Collaborators:
Dana-Farber Cancer Institute Massachusetts General Hospital Mayo Clinic National Cancer Institute (NCI) The Wistar Institute University of Rochester